Leprosy and the natural selection for psoriasis

Medical Hypotheses

Volumn 78, Issue 1, 2012, Pages 183-190

  Bassukas, Ioannis D ^a   Gaitanis, Georgios ^a   Hundeiker, Max ^b  

^a UNIVERSITY OF IOANNINA   (Greece)

^b UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; HLA ANTIGEN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; TOLL LIKE RECEPTOR;

ARTICLE; ATYPICAL MYCOBACTERIOSIS; DISEASE RESISTANCE; GENETIC EPIDEMIOLOGY; GENETIC POLYMORPHISM; GENETIC RESISTANCE; GENOTYPE; HUMAN; INNATE IMMUNITY; LEPROSY; NATURAL SELECTION; PATHOPHYSIOLOGY; PHENOTYPE; PREVALENCE; PSORIASIS; SKIN DISEASE;

EUROPEAN CONTINENTAL ANCESTRY GROUP; GENETIC PREDISPOSITION TO DISEASE; HISTORY, MEDIEVAL; HUMANS; IMMUNITY, INNATE; LEPROSY; MITOGEN-ACTIVATED PROTEIN KINASE 3; MODELS, IMMUNOLOGICAL; PREVALENCE; PSORIASIS; RECEPTOR, ERBB-2; SELECTION, GENETIC; TOLL-LIKE RECEPTORS;

EID: 83155173944     PISSN: 03069877     EISSN: 15322777     Source Type: Journal    
DOI: 10.1016/j.mehy.2011.10.022     Document Type: Article

References (173)

1. Britton W.J., Lockwood D.N.J. Leprosy. Lancet 2004, 363:1209-1219.
2. Ridley D.S., Jopling W.H. Classification of leprosy according to immunity. A five-group system. Int J Lepr Other Mycobact Dis 1966, 34:255-273.
3. Jacobson R.R., Krahenbuhl J.L. Leprosy. Lancet 1999, 353:655-660.
4. Cole S.T., Eiglmeier K., Parkhill J., et al. Massive gene decay in the leprosy bacillus. Nature 2001, 409:1007-1011.
5. Alter A., Alcaïs A., Abel L., Schurr E. Leprosy as a genetic model for susceptibility to common infectious diseases. Hum Genet 2008, 123:227-235.
6. Kaplan G., Cohn Z.A. Regulation of cell-mediated immunity in lepromatous leprosy. Lepr Rev 1986, 57(Suppl 2):199-202.
7. Moet F.J., Meima A., Oskam L., Richardus J.H. Risk factors for the development of clinical leprosy among contacts, and their relevance for targeted interventions. Lepr Rev 2004, 75:310-326.
8. Misch E.A., Berrington W.R., Vary J.C., Hawn T.R. Leprosy and the human genome. Microbiol Mol Biol Rev 2010, 74:589-620.
9. Feitosa M.F., Borecki I., Krieger H., Beiguelman B., Rao D.C. The genetic epidemiology of leprosy in a Brazilian population. Am J Hum Genet 1995, 56:1179-1185.
10. Schön M.P., Boehncke W.-H. Psoriasis. N Engl J Med. 2005, 352:1899-1912.
11. Gudjonsson J.E., Elder J.T. Psoriasis: epidemiology. Clin Dermatol 2007, 25:535-546.
12. Krueger G.G., Langley R.G., Leonardi C., et al. A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis. N Engl J Med 2007, 356:580-592.
13. Nickoloff B.J. Skin innate immune system in psoriasis: friend or foe? J Clin Invest 1999, 104:1161-1164.
14. Bos J.D. Psoriasis, innate immunity, and gene pools. J Am Acad Dermatol 2007, 56:468-471.
15. Büchau A.S., Gallo R.L. Innate immunity and antimicrobial defense systems in psoriasis. Clin Dermatol 2007, 25:616-624.
16. Lande R., Gregorio J., Facchinetti V., et al. Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide. Nature 2007, 449:564-569.
17. Sabeti P.C., Varilly P., Fry B., Lohmueller J., et al. Genome-wide detection and characterization of positive selection in human populations. Nature 2007, 449:913-918.
18. Sørensen T., Nielsen G., Andersen P., Teasdale T. Genetic and environmental influences on premature death in adult adoptees. N Engl J Med 1988, 318:727-732.
19. Pickrell J.K., Coop G., Novembre J., et al. Signals of recent positive selection in a worldwide sample of human populations. Genome Res 2009, 19:826-837.
20. Meindl R.S. Hypothesis: a selective advantage for cystic fibrosis heterocygotes. Am J Phys Anthropol 1987, 74:39-45.
21. Wong S.H., Gochhait S., Malhorta D., et al. Leprosy and the adaptation of human Toll-like receptor 1. PLoS Pathol 2010, 6(7):e1000979.
22. Schurr E., Gros P. A common genetic fingerprint in leprosy and Crohn's disease? N Engl J Med 2009, 361:2666-2668.
23. Najarian D.J., Gottlieb A.B. Connections between psoriasis and Crohn's disease. J Am Acad Dermatol 2003, 48:805-821.
24. Raychaudhuri S.P., Farber E.M. The prevalence of psoriasis in the world. J Eur Acad Dermatol Venereol 2001, 15:16-17.
25. McFadden J.P. Hypothesis-the natural selection of psoriasis. Clin Exp Dermatol 1990, 15:39-43.
26. McFadden J.P., Baker B.S., Powles A.V., Fry L. Psoriasis and streptococci: the natural selection of psoriasis revisited. Br J Dermatol 2009, 160:929-937.
27. *06 is not essential for streptococcal-induced psoriasis. Br J Dermatol 2006, 154:850-853.
28. *0602 associates with a twofold higher prevalence of positive streptococcal throat swab at the onset of psoriasis: a case control study. BMC Dermatol 2009, 9:5. 10.1186/1471-5945/9/.
29. Coop G., Pickrell J.K., Novembre J., et al. The role of geography in human adaptation. PLoS Genet 2009, 5(6):e1000500.
30. Henseler T., Christophers E. Disease concomitance in psoriasis. J Am Acad Dermatol 1995, 32:982-986.
31. Wahba A., Dorfman M., Sheskin J. Psoriasis and other common dermatoses in leprosy. Int J Dermatol 1980, 19:93-95.
32. Wahba-Yahav A.V. Disease concomitance in psoriasis. J Am Acad Dermatol 1996, 35:790-791.
33. Dogra S., Kaur I., Kumar B. Leprosy and psoriasis: an enigmatic relationship. Int J Leprosy 2003, 71:341-344.
34. Pavithran K. Psoriasis developing in a patch of leprosy as a Koebner phenomenon. Indian J Lepr 1992, 64:197-199.
35. Nigam P.K., Gupta S.R., Nair A. Leprosy and psoriasis occurring together. Int J Dermatol 1991, 30:676.
36. Sugathan P., Riyaz N. First report of leprosy and psoriasis occurring together. Int J Dermatol 1990, 29:531-532.
37. Kumar B., Raychaudhuri S.P., Vossough S., Farber E.M. The rare co-existence of leprosy and psoriasis. Int J Dermatol 1992, 31:551-554.
38. Nair R.N., Stuart P.E., Nistor I., et al. Sequence and haplotype analysis supports HLA-C as the psoriasis susceptibility 1 gene. Am J Hum Genet 2006, 78:827-851.
39. Alter A., Huong N.T., Singh M., et al. Human leukocyte antigen class I region single-nucleotide polymorphisms are associated with leprosy susceptibility in Vietnam and India. J Infect Dis 2011, 203:1274-1281.
40. Shankarkumar U., Ghosh K., Badakere S., Mohanty D. Novel HLA class I alleles associated with Indian leprosy patients. J Biomed Biotechnol 2003, 3:208-211.
41. Balamurugan A., Sharma S.K., Mehra N.K. Human leukocyte antigen class I supertypes influence susceptibility and severity of tuberculosis. J Infect Dis 2004, 189:805-811.
42. Da Silva S.A., Mazini P.S., Reis P.G., et al. HLA-DR and HLA-DQ alleles in patients from the south of Brazil: markers for leprosy susceptibility and resistance. BMC Infect Dis 2009, 22:134.
43. *10 are associated with resistance and susceptibility, respectively, in Brasilian and Vietnamese leprosy patients. Genes Immun 2007, 8:320-324.
44. *06 and HLA-DRB1 genes in susceptibility to psoriatic arthritis: comparison with psoriasis and undifferentiated inflammatory arthritis. Ann Rheum Dis 2008, 67:677-682.
45. Traupe H., van Gurp P.J., Happle R., Boezeman J., van de Kerkhof P.C. Psoriasis vulgaris, fetal growth, and genomic imprinting. Am J Med Genet 1992, 42:649-654.
46. Peters E.S., Eshiet E.L. Male-female (sex) differences in leprosy patients in South Eastern Nigeria: female present late for diagnosis and treatment and have higher rates of deformity. Lepr Rev 2002, 73:262-267.
47. Monot M., Honoré N., Garnier T., et al. On the origin of leprosy. Science 2005, 308:1040-1042.
48. Monot M., Honoré N., Garnier T., et al. Comparative genomic and phylogeographic analysis of Mycobacterium leprae. Nat Genet 2009, 41:1282-1291.
49. Hill A.V.S. Aspects of genetic susceptibility to human infectious diseases. Ann Rev Genet 2006, 40:469-486.
50. Boldsen J.L. Leprosy and mortality in the Medieval Danish village of Tirup. Am J Phys Anthropol 2005, 126:159-168.
51. Boldsen J.L., Mollerup L. Outside St. Jørgen: Leprosy in the medieval Danish city of Odense. Am J Phys Anthropol 2006, 130:344-351.
52. Boldsen J.L. Leprosy in Medieval Denmark - osteological and epidemiological analyses. Anthropol Anz 2009, 67:407-425.
53. Olsen A.O., Grjibovski A., Magnus P., Tambs K., Harris J.R. Psoriasis in Norway as observed in a population-based Norwegian twin panel. Br J Dermatol 2005, 153:346-351.
54. Vogelsang T.M. Leprosy in Norway. Med Hist 1965, 9:29-35.
55. Wood S.R. A contribution to the history of tuberculosis and leprosy in 19th century Norway. J Roy Soc Med 1991, 84:428-430.
56. Salo W.L., Aufderheide A.C., Buikstra J., Holcomb T.A. Identification of Mycobacterium tuberculosis DNA in a pre-columbian peruvian mummy. Proc Natl Acad Sci USA 1994, 91:2091-2094.
57. Meckowiak P.A., Blos V.T., Aguilar M., Buikstra J.E. On the origin of American tuberculosis. Clin Infect Dis 2005, 41:515-518.
58. Arriaza B.T., Salo W., Aufderheide A.C., Holcomb T.A. Pre-Columbian tuberculosis in northen Chile: molecular and skeletal evidence. Am J Phys Anthropol 1995, 98:37-45.
59. Boldsen J.L. Leprosy in the early medieval Lauchheim community. Am J Phys Anthropol 2008, 135:301-310.
60. Glickman F.S. Lepra, psora, psoriasis. J Am Acad Dermatol 1986, 14:863-866.
61. Jopling W.H., Jones B.E.A. Psoriasis and leprosy. J Am Acad Dermatol 1990, 22:321.
62. Nestle F.O., Kaplan D.H., Barker J. Mechanisms of disease: psoriasis. N Engl J Med 2009, 361:496-509.
63. Zias J., Mitchell P. Psoriatic arthritis in a fifth-century Judean Desert monastery. Am J Phys Anthropol 1996, 101:491-502.
64. Zhang F.R., Huang W., Chen S.M., et al. Genomwide association study of leprosy. N Engl J Med 2009, 361:2609-2618.
65. Singh N., Arora V.K., Jain A., Bhattacharya S.N., Shatia A. Cytology of testicular changes in leprosy. Acta Cytol 2002, 46:659-663.
66. Saporta L., Yuksel A. Androgenic status in patients with lepromatous leprosy. Br J Urol 1994, 74:221-224.
67. Kannan V., Vijaya G. Endocrine testicular functions in leprosy. Horm Metab Res 1984, 16:146-150.
68. Aggrawal K., Madhu S.V., Aggrawal K., Kannan A.T. Hypogonadism in male Leprosy patients - a study from rural Uttar pradesh. J Commun Dis 2005, 37:219-225.
69. Dass J., Murugesan K., Laumas K.R., Deo M.G., Kandhari K.C., Bhutani L.K. Androgenic status of lepromatous leprosy patients with gynecomastia. Int J Lepr Other Mycobact Dis 1976, 44:469-474.
70. Roy R.G., Kar H.K., Murthy N.N. Gynaecomastia in leprosy in three districts of Tamil Nadu. Indian J Lepr 1984, 56:578-586.
71. Neena K., Ammini A.C., Singh M., Pandhi R.K. Ovarian function in female patients with multibacillary leprosy. Int J Lepr Other Mycobact Dis 2003, 71:101-105.
72. Saunderson P., Gebre S., Desta K., Byass P. The ALERT MDT field evaluation study (AMFES): a descriptive study of leprosy in Ethiopia. Patients, methods and baseline characteristics. Lepr Rev 2000, 71:273-284.
73. Mascie-Taylor C.G. Endemic disease, nutrition and fertility in developing countries. J Biosoc Sci 1992, 24:355-356.
74. Duncan M.E. An historical and clinical review of the interaction of leprosy and pregnancy: a cycle to be broken. Soc Sci Med 1993, 37:457-472.
75. Duncan M.E. Pregnancy and leprosy neuropathy. Indian J Lepr 1996, 68:23-34.
76. Lockwood D.N., Sinha H.H. Pregnancy and leprosy: a comprehensive literature review. Int J Lepr Other Mycobact Dis 1999, 67:6-12.
77. Dissanayake S. Relative lack of clinical disease among household contacts of tuberculosis patients compared to leprosy households. Trans Roy Soc Trop Med Hyg 2004, 98:156-164.
78. Fischer E., De Vlas S., Meima A., Habbema D., Richardus J. Different mechanisms for heterogeneity in leprosy susceptibility can explain disease clustering within households. PLoS ONE 2010, 5(11):e14061.
79. Bennike P., Lewis M.E., Schutkowski H., Valentin F. Comparison of child morbidity in two contrasting medieval cemeteries from Denmark. Am J Phys Anthropol 2005, 128:734-746.
80. Duncan M.E., Miko T., Howe R., et al. Growth and development of children of mothers with leprosy and healthy controls. Ethiop Med J 2007, 45(Suppl 1):9-23.
81. Vlassoff C., Khot S., Rao S. Double jeopardy: women and leprosy in India. World Health Stat Q 1996, 49:120-126.
82. Morrison A. A woman with leprosy is in double jeopardy. Lepr Rev 2000, 71:128-143.
83. Shale M.J. Women with leprosy. A woman with leprosy is in double jeopardy. Lepr Rev 2000, 71:5-17.
84. Chaturvedi S.K., Singh G., Gupta N. Stigma experience in skin disorders: an Indian perspective. Dermatol Clin 2005, 23:635-642.
85. Dzierzykray-Rogalski T. Paleopathology of the Ptolemaic inhabitants of Dakhleh Oasis (Egypt). J Hum Evolut 1980, 9:71-74.
86. Jacob J.T., Franco-Paredes C. The stigmatization of leprosy in India and its impact on future approaches to elimination and control. PLos Negl Trop Dis 2008, 2(1):e113.
87. Jankauskas R., Urbanavicius A. Diseases in European historical populations and their effects on individuals and society. Coll Anthropol 1998, 22:465-476.
88. Seeger J.D., Lanza L.L., West W.A., Fernandez C., Rivero E. Pregnancy and pregnancy outcome among women with inflammatory skin diseases. Dermatology 2007, 214:32-39.
89. Yang Y.W., Chen C.S., Chen Y.H., Lin H.C. Psoriasis and pregnancy outcomes: a nationwide population-based study. J Am Acad Dermatol 2011, 64:71-77.
90. Russell JC. In: Cipolla CM, editor. The Fontana Economic History of Europe. The Middle Ages. Collins/Fontana Books, London - Glasgow 1972.
91. Lowes M.A., Bowbock A.M., Krueger J.G. Pathogenesis and therapy of psoriasis. Nature 2007, 445:866-873.
92. Mackenzie B., Kastelein R.A., Cua D.J. Understanding the IL-23-IL-17 immune pathway. Trends Immunol 2006, 27:17-23.
93. Guttman-Yasky E., Krueger J.G. Psoriasis: evolution of pathogenic concepts and new therapies through phases of translational research. Br J Dermatol 2007, 157:1103-1115.
94. Sugiyama H., Gyulai R., Toichi E., et al. Dysfunctional blood and target tissue CD4+CD25 high regulatory T cells in psoriasis: mechanism underlying unrestrained pathogenic effector T cell proliferation. J Immunol 2005, 174:164-173.
95. Kagami S., Rizzo H.L., Lee J.J., Koguchi Y., Blauvelt A. Circulating Th17, Th22, and Th1 cells are increased in psoriasis. J Invest Dermatol 2010, 130:1373-1383.
96. Vannberg F.O., Chapman S.J., Hill A.V. Human genetic susceptibility to intracellular pathogens. Immunol Rev 2011, 240:105-116.
97. Stanley S.J., Howland C., Stone M.M., Sutherland I. BCG vaccination of children against leprosy in Uganda: final results. J Hyg (Lond) 1981, 87:233-248.
98. Convit J., Smith P.G., Zuniga M., et al. BCG vaccination protects against leprosy in Venezuela: a case-control study. Int J Lepr Other Mycobact Dis 1993, 61:185-191.
99. Cunha S.S., Rodrigues L.C., Pedrosa V., et al. Neonatal BCG protection against leprosy: a study in Manaus, Brazilian Amazon. Lepr Rev 2004, 75:357-366.
100. Tsiouri G., Gaitanis G., Kiorpelidou D., et al. Tuberculin sin test overestimates tuberculosis hypersensitivity in adult patient with psoriasis. Dermatology 2009, 219:119-125.
101. Bassukas I., Kosmidou M., Gaitanis G., Tsiouri G., Tsianos E. Patients with psoriasis are more likely to be treated for latent tuberculosis infection prior to biologics than patients with inflammatory bowel disease. Acta Derm Venereol 2011, 91:444-446.
102. Bassukas I.D., Gaitanis G., Constantopoulos S. Diagnosis of tuberculosis in patients with psoriasis: the need for a modified approach. Eur Respir J 2011, 38:231-232.
103. Goujon C., Gormand F., Gunera-Saad N., et al. The relevance of diagnostic criteria for latent tuberculosis before initiation of TNF-alpha inhibitors in psoriasis patients. Ann Dermatol Venereol 2010, 137:437-443.
104. Laffitte E., Janssens J.P., Roux-Lombard P., et al. Tuberculosis screening in patients with psoriasis before antitumour necrosis factor therapy: comparison of an interferon-γ release assay vs. tuberculin skin test. Br J Dermatol 2009, 161:797-800.
105. Sanchez-Moya A.I., Dauden E. Diagnosing latent tuberculosis infection in psoriatic patients under anti-TNFα treatment. Every new solution breeds new doubts. Br J Dermatol 2011, 164:208-209.
106. Mazurek G.H., Jereb J., Vernon A., et al. Updated guidelines for using interferon gamma release assays to detect Mycobacterium tuberculosis infection - United States, 2010. MMWR Recomm Rep 2010, 59(RR-5):1-25.
107. Balagon M.V., Walsh D.S., Tan P.L., et al. Improvement in psoriasis after intradermal administration of heat-killed Mycobacterium vaccae. Int J Dermatol 2000, 39:51-58.
108. Rath N., Kar H.K. Efficacy of intradermal heat-killed Mycobacterium w in psoriasis: a pilot study. Int J Dermatol 2003, 42:756-757.
109. Nordeen S.K. The epidemiology of leprosy. Leprosy 1985, 15-30. Churchill-Livingstone, Edinburgh (UK). 2nd ed. J.C. Hastings (Ed.).
110. Meyer C.G., May J., Stark K. Human leukocyte antigens in tuberculosis and leprosy. Trends Microbiol 1998, 6:148-154.
111. Moares M.O., Duppre N.C., Suffys P.N., et al. Tumor necrosis factor-alpha promoter polymorphism TNF2 is associated with stronger delayed-type hypersensitivity reaction in the skin of borderline tuberculoid leprosy patients. Immunogenetics 2001, 53:45-47.
112. Fuentes-Duculan J., Suárez-Fariñas M., Zaba L.C., et al. A subpopulation of CD163-positive macrophages is classically activated in psoriasis. J Invest Dermatol 2010, 130:2412-2422.
113. Albanesi C., Scarponi C., Bosisio D., Sozzani S., Girolomoni G. Immune functions and recruitment of plasmacytoid dendritic cells in psoriasis. Autoimmunity 2010, 43:215-219.
114. Greaves N.W. Neutrophil polymorphonuclears, mediators and pathogenesis of psoriasis. Br J Dermatol 1983, 109:115-118.
115. Lee D.J., Li H., Ochoa M.T., et al. Integrated pathways for neutrophil recruitment and inflammation in leprosy. J Infect Dis 2010, 201:558-569.
116. Rosenberg E.W., Noah P.W., Skinner R.B. Psoriasis is a visible manifestation of skin's defense against micro-organisms. J Dermatol 1994, 21:375-381.
117. Nestle F.O., Di Meglio P., Qin J.Z., Nickoloff B.J. Skin immune sentinels in health and diseases. Nat Rev Immunol 2009, 9:679-691.
118. Goulart L.R., Goulart I.M.B. Leprosy pathogenesis background: a review and lessons from other mycobacterial diseases. Arch Dermatol Res 2009, 301:123-137.
119. Leonardi C.L., Powers J.L., Matheson R.T., et al. Etanercept as monotherapy in patients with psoriasis. N Engl J Med 2003, 349:2014-2022.
120. Fitch E., Harper E., Skorcheva I., et al. Pathophysiology of psoriasis: recent advances on IL-23 and Th17 cytokines. Curr Rheumatol Rep 2007, 9:461-467.
121. Bachelez H. Immunopathogenesis of psoriasis: recent insights on the role of adaptive and innate immunity. J Autoimmun 2005, 25:69-73.
122. Bos J.D., De Rie M.A., Teunissen M.B.M., Piskin G. Psoriasis: dysregulation of innate immunity. Br J Dermatol 2005, 152:1098-1107.
123. Akira S., Uematsu S., Takeuchi O. Pathogen recognition and innate immunity. Cell 2006, 124:783-801.
124. Beutler B. Inferences, questions and possibilities in Toll-like receptor signalling. Nature 2004, 430:257-263.
125. Texereau J., Chiche J.-D., Taylor W., Choukroun G., Comba B., Mira J.-P. The importance of Toll-like receptor 2 polymorphisms in severe infections. Clin Infect Dis 2005, 41:S408-S415.
126. Zhu J, Mohan C. Toll-like receptor signaling pathways - therapeutic opportunities. Mediat Inflammat, 2010. doi:10.1155/2010/781235.
127. Terhorst D., Kalali B.N., Ollert M., Ring J., Mempel M. The role of toll-like receptors in host defenses and their relevance to dermatologic diseases. Am J Clin Dermatol 2010, 11:1-10.
128. Underhill D.M., Ozinsky A., Smith K.D., Aderem A. Toll-like receptor 2 mediates mycobacteria-induced proinflammatory signalling in macrophages. Proc Natl Acad Sci USA 1999, 96:14459-14463.
129. Bochud P.Y., Hawn T.R., Aderem A. Cutting edge: a Toll-like receptor 2 polymorphism that is associated with lepromatous leprosy is unable to mediate mycobacterial signaling. J Immunol 2003, 170:3451-3454.
130. Krutzik S.R., Ochoa M.T., Siebling P.A., et al. Activation and regulation of Toll-like receptors 2 and 1 in human leprosy. Nat Med 2003, 9:525-532.
131. Takeuchi O., Sato S., Horiuchi T., Hoshino K., Takeda K., Dong Z., et al. Cutting edge: role of Toll-like receptor 1 in mediating immune response to microbial lipoproteins. J Immunol 2002, 169:10-14.
132. Mira M.T. Genetic host resistance and susceptibility to leprosy. Microb Infect 2006, 8:1124-1131.
133. Curry J.L., Qin J.-Z., Bonish B., et al. Innate immune-related receptors in normal and psoriatic skin. Arch Pathol Lab Med 2003, 127:178-186.
134. Candia L., Marquez J., Hernandez C., Zea A.H., Espinoza L.R. Toll-like receptor-2 expression is upregulated in antigen-presenting cells from patients with psoriatic arthritis: a pathogenic role for innate immunity? J Rheumatol 2007, 34:374-379.
135. Baker B.S., Ovigne J.-M., Powles A.V., Corcoran S., Fry L. Normal keratinocytes express Toll-like receptors (TLRs) 1, 2, and 5: modulation of TLR expression in chronic plaque psoriasis. Brit J Dermatol 2003, 148:670-679.
136. Begon E., Michel L., Flageul B., et al. Expression, subcellular localization and cytokinic modulation of Toll-like receptors (TLRs) in normal human keratinocytes: TLR2 up-regulation in psoriatic skin. Eur J Dermatol 2007, 17:497-506.
137. Kang T.J., Chae G.T. Detection of Toll-like receptor 2 (TLR2) mutation in the lepromatous leprosy patients. FEMS Immunol Med Microbiol. 2001, 31:53-58.
138. Ogus A.C., Yoldas B., Ozdemir T., et al. The Arg753GLn polymorphism of the human toll-like receptor 2 gene in tuberculosis disease. Eur Respir J 2004, 23:219-223.
139. Yim J.J., Lee H.W., Lee H.S., et al. The association between microsatellite polymorphisms in intron II of the human Toll-like receptor 2 gene and tuberculosis among Koreans. Genes Immun 2006, 7:150-155.
140. Bochud P.-Y., Hawn T.R., Siddiqui M.R., et al. Toll-like receptor 2 (TLR2) polymorphisms are associated with reversal reaction in leprosy. J Infect Dis 2008, 197:253-261.
141. Schuring R.P., Hamann L., Faber W.R., et al. Polymorphism N248S in the human Toll-like receptor 1 gene is related to leprosy and leprosy reactions. J Infect Dis 2009, 199:1816-1819.
142. Johnson C.M., Lyle E.A., Omeuti K.O., et al. Cutting edge: A common polymorphism impairs cell surface trafficking and functional responses of TLR1 but protects against leprosy. J Immunol 2007, 15:7520-7524.
143. Kang T.J., Lee S.-B., Chae G.-T. A polymorphism in the toll-like receptor 2 is associated with IL-12 production from monocyte in lepromatous leprosy. Cytokine 2002, 20:56-62.
144. Van de Voss E., Hoeve M.A., Ottenhoff T.H. Human genetics of intracellular infectious diseases: molecular and cellular immunity against mycobacteria and salmonellae. Lancet Infect Dis 2004, 4:739-749.
145. Ottenhoff T.H.M., Verreck F.A.W., Hoeve M.A., van de Vosse E. Control of human host immunity to mycobacteria. Tuberculosis 2005, 85:53-64.
146. Torti D.C. Feldman SR Interleukin-12, interleukin-23, and psoriasis: current progress. J Am Acad Dermatol 2007, 57:1059-1068.
147. Doffinger R., Dupuis S., Picard C., Fieschi C., Feinberg J., Barcenas-Morales G., et al. Inherited disorders of IL-12- and IFNgamma-mediated immunity: a molecular genetics update. Mol Immunol 2002, 38:903-909.
148. Morahan G., Kaur G., Singh M., Rapthap C.C., Kumar N., Katoch K., et al. Association of variants in the IL12B gene with leprosy and tuberculosis. Tissue Antigens 2007, 69(S1):234-236.
149. Ohyama H., Ogata K., Takeuchi K., et al. Polymorphism of the 5' flanking region of the IL-12 receptor beta2 gene partially determines the clinical types of leprosy through impaired transcriptional activity. J Clin Pathol 2005, 58:740-743.
150. Cargill M., Schrodi S.J., Chang M., et al. A large-scale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasis-risk genes. Am J Hum Genet 2007, 80:273-290.
151. Liu Y., Helms C., Liao W., et al. A genome-wide association study of psoriasis and psoriatic arthritis identifies new disease loci. PLoS Genet 2008, 4(28):e1000041.
152. Tapinos N., Ohnishi M., Rambukkana A. ErbB2 receptor tyrosine kinase signaling mediates early demyelination induced by leprosy bacilli. Nat Med 2006, 12:961-966.
153. Noon L.A., Lloyd A.C. Treating leprosy: an Erb-al remedy. Trends Pharmacol Sci 2007, 28:103-105.
154. Piepkorn M., Predd H., Underwood R., Cook P. Proliferation-differentiation relationships in the expression of heparin-binding epidermal growth factor-related factors and erbB receptors by normal and psoriatic human keratinocytes. Arch Dermatol Res 2003, 295:93-101.
155. Yoshida A., Kanno H., Watabe D., Akasaka T., Sawai T. The role of heparin-binding EGF-like growth factor and amphiregulin in the epidermal proliferation of psoriasis in cooperation with TNFalpha. Arch Dermatol Res 2008, 300:37-45.
156. Eckert R.L., Efimova T., Balasubramanian S., Crish J.F., Bone F., Dashti S. P38 mitogen-activated protein kinases on the body surface - a function for p38 delta. J Invest Dermatol 2003, 120:823-828.
157. Efimova T., Broome A.M., Eckert R.L. A regulatory role for p38 delta MAPK in keratinocyte differentiation. Evidence for p38 delta-ERK1/2 complex formation. J Biol Chem 2003, 278:34277-34285.
158. Yu X.-J., Li C.Y., Dai H.Y., et al. Expression and localization of the activated mitogen-activated protein kinase in lesional psoriatic skin. Exp Mol Pathol 2007, 83:413-418.
159. Johansen C., Kragballe K., Westergaard M., Henningsen J., Kristiansen K., Iversen L. The mitogen-activated protein kinases p38 and ERK1/2 are increased in lesional psoriatic skin. Br J Dermatol. 2005, 152:37-42.
160. Kiguchi K., Bol D., Carbajal S., et al. Constitutive expression of erbB2 in epidermis of transgenic mice results in epidermal hyperproliferation and spontaneous skin tumor development. Oncogene 2000, 19:4243-4254.
161. Johnston A., Gudjonsson J.E., Aphale A., Guzman A.M., Stoll S.W., Elder J.T. EGFR and IL-1 signaling synergistically promote keratinocyte antimicrobial defenses in a differentiation-dependent manner. J Invest Dermatol 2011, 131:329-337.
162. Bhagavathula N., Nerusu K.C., Fisher G.J., et al. Amphiregulin and epidermal hyperplasia: amphiregulin is required to maintain the psoriatic phenotype of human skin grafts on severe combined immunodeficient mice. Am J Pathol 2005, 166:1009-1016.
163. Cook P.W., Brown J.R., Cornell K.A., Pittelkow M.R. Suprabasal expression of human amphiregulin in the epidermis of transgenic mice induces a severe, early-onset, psoriasis-like skin pathology: expression of amphiregulin in the basal epidermis is also associated with synovitis. Exp Dermatol 2004, 13:347-356.
164. Kimura H., Fischer W.H., Schubert D. Structure, expression and function of a schwannoma-derived growth factor. Nature 1990, 348:257-260.
165. Cook P.W., Piepkorn M., Clegg C.H., et al. Transgenic expression of the human amphiregulin gene induces a psoriasis-like phenotype. J Clin Invest 1997, 100:2286-2294.
166. Nilsson A., Moller K., Dahlin L., Lundborg G., Kanje M. Early changes in gene expression in the dorsal root ganglia after transaction of the sciatic nerve; effects of amphiregulin and PAI-1 on regeneration. Mol Brain Res 2005, 136:65-74.
167. Manchester K. Tuberculosis and leprosy in antiquity: an interpretation. Med Hist 1984, 28:162-173.
168. Chaussinand R. Tuberculose et lepre, maladies antagonistiques. Int J Lepr 1948, 16:431-438.
169. Lietan T., Porco T., Blower S. Leprosy and tuberculosis: the epidemiological consequences of cross-immunity. Am J Public Health 1997, 87:1923-1927.
170. Donoghue H.D., Marcsik A., Matheson C., et al. Co-infection of Mycobacterium tuberculosis and Mycobacterium leprae in human archaeological samples: a possible explanation for the historical decline of leprosy. Proc Biol Sci 2005, 272:389-394.
171. Manolio T.A., Collins F.S., Cox N.J., et al. Finding the missing heritability of complex diseases. Nature 2009, 461:747-753.
172. Zondervan K.T., Cardon L.R. Designing candidate gene and genome-wide case-control association studies. Nat Protocols 2007, 2:2492-2501.
173. Bach J.-F. The effect of infections on susceptibility to autoimmune and allergic diseases. N Engl J Med 2002, 347:911-920.